Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients

CHIR-Net39 enrolled

Overview

In a prospective observational study the incidence of Heparin-induced Thrombocytopenia (HIT) Type 2 after orthotopic liver transplantation, associated factors, and hemostaseological findings in thrombocytes and anti-body patterns is going to be investigated.

The investigators examined the frequency of anti-PF4/heparin antibodies (IgG/M/A; EIA) and their functional activity (HIPA) in 38 whole organ deceased donor liver transplant recipients. Additionally, demographic, clinical, donor- and recipient-specific parameters and laboratory findings (ALAT, ASAT, cholinesterase) were investigated.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Heparin-induced Thrombocytopenia Liver Transplantation

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * all consecutive liver transplant recipients between 01/2010 and 08/2011 who * were transplanted at our center after allocation of a liver graft via Eurotransplant Exclusion Criteria: * patient's refusal to participate in prospective observation

Locations (1)

Klinikum rechts der Isar der TU München

Munich, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.